These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35315687)

  • 1. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
    Wire MB; Magee M; Ackerman P; Llamoso C; Moore K
    HIV Res Clin Pract; 2021 Dec; 23(1):1-8. PubMed ID: 35285786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
    Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
    Magee M; Slater J; Mannino F; Ackerman P; Llamoso C; Moore K
    J Clin Pharmacol; 2021 Jul; 61(7):939-953. PubMed ID: 33368327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Majeed SR; West S; Ling KH; Das M; Kearney BP
    Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
    Salama E; Hill L; Patel N; Best BM; Momper JD
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
    Crutchley RD; Guduru RC; Cheng AM
    HIV AIDS (Auckl); 2016; 8():47-65. PubMed ID: 27022304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
    Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
    J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.